全病灶表观扩散系数分析在前列腺癌主动监测患者结局预测中的作用
本研究纳入72例接受主动监测的前列腺癌患者,均在监测开始时行MRI-超声融合靶向活检、活检区域可见MRI病灶,并完成间隔至少一年的3T基线和随访MRI。结果显示基线全病灶ADC指标(尤其是ADC0-10th-percentile)在ADC图上病灶增长≥50%的病灶中显著更低,ADC0-10th-percentile预测≥50%增长的AUC为0.754;随访活检Gleason评分≥3+4的患者ADC图上肿瘤体积平均百分比变化为62.3%±26.9%,其余患者为3.6%±64.6%(P=0.050)。
要点
- 基线全病灶ADC0-10th-percentile在ADC图上增长≥50%的病灶中显著更低(585±308 vs 911±336,P=0.001)。
- ADC0-10th-percentile预测病灶在ADC图上增长≥50%的AUC为0.754。
- 随访活检Gleason评分≥3+4者ADC图上肿瘤体积平均百分比变化为62.3%±26.9%,其余为3.6%±64.6%(P=0.050)。
核心结论
- 初步结果表明3D全病灶ADC分析在前列腺癌主动监测中可能具有作用。
研究设计与样本
- 纳入72例主动监测前列腺癌患者,均在监测开始时行MRI-超声融合靶向活检、活检肿瘤区域可见MRI病灶,并完成间隔至少一年的3T基线和随访MRI;其中30例在随访MRI后另行MRI-超声融合靶向活检。
关键影像表现/征象
- 基线全病灶平均ADC、ADC0-10th-percentile、ADC10-25th-percentile和ADC25-50th-percentile在ADC图上增长≥50%的病灶中均显著低于其余病灶(均P≤0.007)。
- ADC0-10th-percentile在增长≥50%与未增长≥50%病灶间差异最强(585±308 vs 911±336,P=0.001)。
- 随访活检Gleason评分≥3+4患者ADC图上肿瘤体积平均百分比变化为62.3%±26.9%,其余患者为3.6%±64.6%(P=0.050)。
诊断标准与关键数值
- 全病灶ADC指标及病灶体积基于基线和随访ADC图上放置的3D全病灶感兴趣体积计算。
- ADC0-10th-percentile预测ADC图上病灶增长≥50%的AUC为0.754。
- ADC图上病灶增长≥50%为结局指标之一。
- 随访活检Gleason评分≥3+4为结局指标之一。
临床应用与阅片要点
- 作者认为3D全病灶ADC分析在前列腺癌主动监测中可能具有作用。
局限性
- 原文结论表述为初步结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To explore the role of whole-lesion apparent diffusion coefficient (ADC) analysis for predicting outcomes in prostate cancer patients on active surveillance.
METHODS: This study included 72 prostate cancer patients who underwent MRI-ultrasound fusion-targeted biopsy at the initiation of active surveillance, had a visible MRI lesion in the region of tumor on biopsy, and underwent 3T baseline and follow-up MRI examinations separated by at least one year. Thirty of the patients also underwent an additional MRI-ultrasound fusion-targeted biopsy after the follow-up MRI. Whole-lesion ADC metrics and lesion volumes were computed from 3D whole-lesion volumes-of-interest placed on lesions on the baseline and follow-up ADC maps. The percent change in lesion volume on the ADC map between the serial examinations was computed. Statistical analysis included unpaired t tests, ROC analysis, and Fisher's exact test.
RESULTS: Baseline mean ADC, ADC0-10th-percentile, ADC10-25th-percentile, and ADC25-50th-percentile were all significantly lower in lesions exhibiting ≥50% growth on the ADC map compared with remaining lesions (all P ≤ 0.007), with strongest difference between lesions with and without ≥50% growth observed for ADC0-10th-percentile (585 ± 308 vs. 911 ± 336; P = 0.001). ADC0-10th-percentile achieved highest performance for predicting ≥50% growth (AUC = 0.754). Mean percent change in tumor volume on the ADC map was 62.3% ± 26.9% in patients with GS ≥ 3 + 4 on follow-up biopsy compared with 3.6% ± 64.6% in remaining patients (P = 0.050).
CONCLUSION: Our preliminary results suggest a role for 3D whole-lesion ADC analysis in prostate cancer active surveillance.
引用
- Tamada T, Dani H, Taneja SS, et al. The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance. Abdom Radiol (NY). 2017. PMID: 28396920. doi:10.1007/s00261-017-1135-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。